Capricor drops as deramiocel OLE data fails to quell regulatory concerns

Data ReadoutnegativederamiocelNegative

AI Analysis

Summary

Capricor's stock declined following disappointing deramiocel open-label extension (OLE) data that failed to address regulatory concerns about the program.

Outcome Details

OLE data failed to quell regulatory concerns

Importance:6/10

Sentiment:

-0.65

clinical dataregulatory concernsstock decline

Related Companies

$CAPR

Read the original article

Published by Seeking Alpha Healthcare on October 5, 2026 4:12 PM

Read Original